Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00437255 · ClinicalTrials.gov registry record · Phase 4
Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis
A Phase 4 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 122
- Enrollment target
NCT00437255 is a Phase 4 study that has completed, run by Galderma R&D. The registered enrollment target is 122 participants.
The verdict
NCT00437255, a Phase 4 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 122 participants
- Enrollment target
Study Summary
Evaluate the efficacy of Clobex® Spray as compared to Taclonex® Ointment in terms of Overall Disease Severity and Investigator Global Assessment.
Interventions
- DRUG Clobetasol Propionate, 0.05%
- DRUG Calcipotriene and betamethasone dipropionate ointment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2006-08 |
| Est. Completion | 2007-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00437255
The ClinicalTrials.gov registry entry for NCT00437255 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Clobetasol Propionate, 0.05% is the first listed.
NCT00437255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00437255 about?
NCT00437255 is a clinical study titled "Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis". Evaluate the efficacy of Clobex® Spray as compared to Taclonex® Ointment in terms of Overall Disease Severity and Investigator Global Assessment.
What is the current status of trial NCT00437255?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 122 participants. The study started on 2006-08. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00437255?
The interventions under investigation include: Clobetasol Propionate, 0.05% (DRUG), Calcipotriene and betamethasone dipropionate ointment (DRUG).
Who is sponsoring clinical trial NCT00437255?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.